Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy

Fig. 5

Comparisons of PFS (or OS) and ORR between SpHe-comut+ and SpHe-comut− groups across different cohorts. A Kaplan–Meier survival curves of PFS comparing SpHe-comut+ and SpHe-comut− groups among patients with melanoma treated with anti-PD-(L)1 or anti-CTLA-4 therapy from the Inova cohort. B Comparison of ORR between the SpHe-comut+ and SpHe-comut− groups from the Inova cohort. C Kaplan–Meier survival curves of PFS comparing the SpHe-comut+ and SpHe-comut− groups in patients with NSCLC treated with anti-PD-1 therapy from the Rizvi cohort. D Comparison of ORR between the SpHe-comut+ and SpHe-comut− groups from the Rizvi cohort. E Kaplan–Meier survival curves of OS comparing SpHe-comut+ and SpHe-comut− groups in patients with pan-cancer treated with anti-CTLA4 or anti-PD-(L)1 therapy from the Miao cohorts. F Comparison of ORR between the SpHe-comut+ and SpHe-comut− groups from the Miao cohort

Back to article page